These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

386 related items for PubMed ID: 29592773

  • 1. Effect of changing from preserved prostaglandins to preservative-free tafluprost in patients with glaucoma on tear film thickness.
    Hommer A, Schmidl D, Kromus M, Bata AM, Fondi K, Werkmeister RM, Baar C, Schmetterer L, Garhöfer G.
    Eur J Ophthalmol; 2018 Jul; 28(4):385-392. PubMed ID: 29592773
    [Abstract] [Full Text] [Related]

  • 2. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
    Uusitalo H, Chen E, Pfeiffer N, Brignole-Baudouin F, Kaarniranta K, Leino M, Puska P, Palmgren E, Hamacher T, Hofmann G, Petzold G, Richter U, Riedel T, Winter M, Ropo A.
    Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237
    [Abstract] [Full Text] [Related]

  • 3. Tear clearance and ocular symptoms in patients treated with preservative-free prostaglandins.
    Giménez-Gómez R, García-Catalán MR, Gallardo-Galera JM.
    Arch Soc Esp Oftalmol; 2013 Mar; 88(3):88-91. PubMed ID: 23473084
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma.
    Hommer A, Mohammed Ramez O, Burchert M, Kimmich F.
    Curr Med Res Opin; 2010 Aug; 26(8):1905-13. PubMed ID: 20553122
    [Abstract] [Full Text] [Related]

  • 7. Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension.
    Erb C, Lanzl I, Seidova SF, Kimmich F.
    Adv Ther; 2011 Jul; 28(7):575-85. PubMed ID: 21725844
    [Abstract] [Full Text] [Related]

  • 8. Comparing the tolerability of preservative-free tafluprost versus preserved latanoprost in the management of glaucoma and ocular hypertension - an observer blinded active-control trial.
    Brinkman D, McSwiney T, James M.
    Ir J Med Sci; 2024 Oct; 193(5):2589-2595. PubMed ID: 38748195
    [Abstract] [Full Text] [Related]

  • 9. Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials.
    Uusitalo H, Egorov E, Kaarniranta K, Astakhov Y, Ropo A.
    Clin Ophthalmol; 2016 Oct; 10():445-54. PubMed ID: 27041987
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Tafluprost/Timolol: A Review in Open-Angle Glaucoma or Ocular Hypertension.
    Hoy SM.
    Drugs; 2015 Oct; 75(15):1807-13. PubMed ID: 26431840
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients.
    Ruangvaravate N, Choojun K, Srikulsasitorn B, Chokboonpiem J, Asanatong D, Trakanwitthayarak S.
    Clin Ophthalmol; 2020 Oct; 14():3109-3119. PubMed ID: 33116362
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Meibomian gland dropout rate as a method to assess meibomian gland morphologic changes during use of preservative-containing or preservative-free topical prostaglandin analogues.
    Lee SY, Lee K, Park CK, Kim S, Bae HW, Seong GJ, Kim CY.
    PLoS One; 2019 Oct; 14(6):e0218886. PubMed ID: 31242247
    [Abstract] [Full Text] [Related]

  • 17. Tafluprost: the first preservative-free prostaglandin to treat open-angle glaucoma and ocular hypertension.
    Swymer C, Neville MW.
    Ann Pharmacother; 2012 Nov; 46(11):1506-10. PubMed ID: 23092867
    [Abstract] [Full Text] [Related]

  • 18. Additive Effect of preservative-free sodium hyaluronate 0.1% in treatment of dry eye syndrome with diquafosol 3% eye drops.
    Hwang HS, Sung YM, Lee WS, Kim EC.
    Cornea; 2014 Sep; 33(9):935-41. PubMed ID: 25055152
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.